Whilst total CD44 expression is not considered to confer a survival advantage to head and neck cancers, further investigation is warranted to determine whether its variant isoforms might offer a survival advantage or stem cell properties to malignant keratinocytes. Here, CD44 is linked to head and neck cancer.